Axoft Launches Brain Implant Technology to Treat Long-Term Neurological Disorders and is Granted FDA Breakthrough Device Designation
yahoo.com
news
2022-10-18 12:00:00

Neurotechnology startup raises $8 million seed round led by The Engine

BOSTON, October 18, 2022--(BUSINESS WIRE)--Axoft, a neurotechnology company, today launched and announced FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders. The company secured $8 million in capital to fund pre-clinical studies with the FDA and to scale up prototypes of its neural implants "as soft as the brain." The seed round investment, led by The Engine, the venture firm spun out of MIT that invests in early-stage Tough Tech companies, included investors: Ab Initio Capital, Decent Capital, Alumni Ventures, Safar Partners, AIBasis, LiquidMetal VC, Taihill Venture, AMINO Capital, Blindspot Ventures and Mintz.
